PDF Cover

Olutasidenib Market

The market for Olutasidenib was estimated at $312 million in 2024; it is anticipated to increase to $441 million by 2030, with projections indicating growth to around $587 million by 2035.

Report ID:DS1802386
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Olutasidenib
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Olutasidenib Market Outlook

Revenue, 2024

$312M

Forecast, 2034

$554M

CAGR, 2025 - 2034

5.9%

The Olutasidenib industry revenue is expected to be around $330.7 million in 2025 and expected to showcase growth with 5.9% CAGR between 2025 and 2034. The market continues to attract considerable attention within the oncology sector due to the growing emphasis on precision medicine and targeted cancer therapies. Increasing prevalence of acute myeloid leukemia, rising adoption of molecular diagnostic testing, and expanding awareness of mutation-specific treatment approaches are key factors supporting market growth. Healthcare providers are increasingly integrating biomarker-driven therapies into treatment protocols to improve patient outcomes and optimize therapeutic effectiveness. Furthermore, ongoing investments in oncology research, supportive regulatory pathways for innovative cancer treatments, and expanding access to advanced hematology care are reinforcing the market's importance. These factors continue to strengthen the commercial relevance of olutasidenib in the evolving leukemia treatment landscape.

Olutasidenib, also known as Rezlidhia, is an oral targeted therapy designed to inhibit mutant isocitrate dehydrogenase 1, a genetic alteration associated with certain cases of acute myeloid leukemia. The drug is primarily used for patients with relapsed or refractory acute myeloid leukemia harboring an IDH1 mutation, providing a precision medicine approach to disease management. Its targeted mechanism helps address specific molecular drivers of cancer progression, distinguishing it from conventional chemotherapy-based treatments. Demand for olutasidenib is being supported by increasing utilization of genomic profiling, growing adoption of personalized oncology strategies, and broader implementation of companion diagnostic testing. In addition, expanding clinical research focused on mutation-targeted therapies, rising investments in hematologic cancer innovation, and the development of combination treatment approaches are creating new opportunities for market expansion. These trends continue to strengthen the role of olutasidenib within the advanced oncology therapeutics market.

Olutasidenib market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Olutasidenib Market Outlook

Market Key Insights

  • The Olutasidenib market is projected to grow from $312.3 million in 2024 to $554 million in 2034. This represents a CAGR of 5.9%, reflecting rising demand across Cancer Treatment, Clinical Trials, and Research & Development.

  • Forma Therapeutics, Menarini Silicon Biosystems, BridgeBio Pharma are among the leading players in this market, shaping its competitive landscape.

  • U.S. and UK are the top markets within the Olutasidenib market and are expected to observe the growth CAGR of 3.8% to 5.7% between 2024 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 6.8% to 8.1%.

  • Transition like Transition from Broad Chemotherapy Approaches to Precision Oncology Treatments has greater influence in U.S. and UK market's value chain; and is expected to add $15 million of additional value to Olutasidenib industry revenue by 2030.

  • The Olutasidenib market is set to add $242 million between 2024 and 2034, with manufacturer targeting Genetic Mutation Disorders Treatment & Cancer Research Application projected to gain a larger market share.

  • With

    revolution in targeted therapies, and

    Urgency for Advanced Treatments in Acute Myeloid Leukemia, Olutasidenib market to expand 77% between 2024 and 2034.

olutasidenib market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Olutasidenib - Country Share Analysis

Opportunities in the Olutasidenib

Ongoing research into combination treatment strategies presents a significant growth opportunity for the olutasidenib market. Pharmaceutical companies and academic institutions are evaluating targeted therapies alongside other oncology treatments to improve patient outcomes and extend therapeutic effectiveness. Strategic collaborations and clinical development programs are accelerating innovation in this area. The clinical trials application is also expected to benefit most as researchers explore new treatment protocols for genetically defined cancer populations. Expanding evidence supporting combination approaches could increase physician confidence and create additional commercial opportunities across advanced oncology care settings.

Growth Opportunities in North America and Europe

North America is the dominant regional market for olutasidenib, supported by advanced oncology infrastructure, widespread adoption of precision medicine, and strong utilization of genomic testing in cancer care. The region benefits from high awareness of acute myeloid leukemia, robust reimbursement frameworks for innovative therapies, and significant investment in targeted oncology research. Key opportunities are emerging from the growing integration of biomarker-driven treatment pathways and increasing use of molecular diagnostics to identify IDH1-mutated patients. Competitive intensity remains high due to the presence of leading pharmaceutical companies developing targeted leukemia therapies and precision oncology solutions. Strategic collaborations between drug developers, cancer centers, and diagnostic providers continue to strengthen market penetration. The United States accounts for the largest share of regional demand owing to its strong clinical research ecosystem, extensive access to specialized hematology services, and continued focus on personalized cancer treatment approaches.
Europe represents a significant market for olutasidenib, driven by expanding precision oncology programs, supportive regulatory pathways for innovative cancer therapies, and increasing investment in hematologic cancer management. Countries such as Germany, France, Italy, and the United Kingdom are enhancing access to genomic testing and personalized treatment strategies through national cancer initiatives and specialized healthcare networks. A major opportunity lies in the increasing adoption of biomarker-based diagnostics, which is improving patient identification and supporting targeted therapy utilization. Competition is characterized by the presence of established oncology drug manufacturers and a growing pipeline of mutation-specific cancer treatments. Market growth is further supported by collaborative research projects, strong academic oncology centers, and rising demand for individualized leukemia treatment solutions. Continued advancements in cancer genomics and precision healthcare are expected to sustain long-term growth across the European olutasidenib market.

Market Dynamics and Supply Chain

01

Driver: Expanding Genomic Testing Adoption and Rising Precision Oncology Utilization

The increasing adoption of genomic testing is also a major driver of the olutasidenib market. Healthcare providers are also incorporating advanced molecular diagnostic technologies into routine oncology practice to identify actionable genetic mutations and support targeted treatment decisions. This trend is also improving detection rates of IDH1-mutated acute myeloid leukemia and expanding the pool of eligible patients. Simultaneously, the growing utilization of precision oncology is also accelerating demand for therapies specifically designed to address molecular disease drivers. Cancer treatment strategies are also increasingly shifting away from broad approaches toward personalized interventions based on genetic profiles. also advances in biomarker analysis, companion diagnostics, and data-driven treatment planning are also strengthening physician confidence in targeted therapies, supporting greater clinical adoption and reinforcing long-term market growth opportunities.
Growing investment in targeted cancer therapeutics is also creating favorable conditions for the olutasidenib market. Pharmaceutical companies, biotechnology firms, and research institutions are also directing significant resources toward the development of mutation-specific treatments for hematologic malignancies. This trend is also supported by advancements in cancer genomics, improved understanding of disease biology, and expanding clinical research focused on personalized medicine. Strategic collaborations among drug developers, diagnostic companies, and healthcare organizations are also accelerating innovation and increasing awareness of targeted treatment options. As precision medicine becomes more integrated into leukemia care, demand for specialized therapies addressing specific genetic alterations is also expected to continue expanding across global oncology markets.
02

Restraint: Limited Eligible Patient Population Restricts Broad Commercial Market Expansion

One of the most significant restraints affecting the olutasidenib market is the relatively small patient population eligible for treatment. The therapy is specifically intended for patients with IDH1-mutated acute myeloid leukemia, making demand dependent on molecular testing and mutation prevalence. While precision medicine improves treatment effectiveness, it also narrows the addressable market. For example, patients lacking the relevant genetic mutation are not suitable candidates, limiting prescription volumes compared with broader oncology therapies. This restricted patient base influences revenue generation potential and can moderate market expansion despite increasing adoption of personalized cancer treatment strategies.
03

Opportunity: IDH1 Mutated Acute Myeloid Leukemia Patients Driving Demand and Asia Pacific Cancer Centers Increasing Targeted Therapy Adoption

A major opportunity for olutasidenib lies in the growing identification of patients with IDH1-mutated acute myeloid leukemia through advanced genomic testing programs. Healthcare systems are increasingly integrating molecular diagnostics into oncology workflows, enabling earlier and more accurate detection of actionable mutations. This trend is expanding the addressable patient population and supporting broader adoption of targeted therapies. The cancer treatment application is expected to experience the strongest growth, particularly in North America and Europe, where precision oncology infrastructure, biomarker testing adoption, and access to specialized hematology care continue to advance rapidly.
The expansion of specialized cancer centers across Asia Pacific is creating favorable conditions for olutasidenib market growth. Countries such as China, Japan, South Korea, and India are investing in precision medicine infrastructure, cancer genomics programs, and advanced diagnostic capabilities. These developments are improving patient access to mutation-specific therapies and supporting broader utilization of targeted oncology treatments. The cancer treatment application is anticipated to witness the highest growth in the region as awareness of personalized medicine increases. Continued healthcare modernization and strategic partnerships are expected to strengthen long-term market penetration opportunities.
04

Challenge: Intense Competition from Alternative Targeted Leukemia Therapies Reduces Adoption

The olutasidenib market faces strong competitive pressure from other targeted therapies and emerging treatment options within the acute myeloid leukemia landscape. Pharmaceutical companies continue introducing innovative precision oncology products aimed at specific genetic mutations and disease pathways. As a result, physicians often have multiple treatment choices when designing patient care plans. For example, competing mutation-targeted therapies and combination treatment regimens may capture a portion of eligible patients, affecting demand for olutasidenib. This competitive environment can influence market share, increase commercial challenges for manufacturers, and intensify pressure on pricing, reimbursement, and long-term growth opportunities.

Supply Chain Landscape

1

Raw Material Providers

ASL BiopharmaAK Scientific Inc
2

API Manufacturers

PharmaronSTA Pharmaceutical Co. Ltd
3

Finished Product Manufacturers

Forma Therapeutics HoldingsCayman Chemical Company
4

Distributors & End-Users

Hospital PharmacySpecialty Pharmacy
Olutasidenib - Supply Chain

Use Cases of Olutasidenib in Cancer Treatment & Research & Development

Cancer Treatment : Cancer treatment is the primary application of olutasidenib, particularly for patients with relapsed or refractory acute myeloid leukemia carrying an IDH1 mutation. The oral capsule formulation is predominantly prescribed in oncology hospitals, hematology centers, and specialized cancer clinics where molecular diagnostics are routinely used to guide therapy selection. Its targeted mechanism provides a precision medicine approach that helps address specific genetic drivers of disease progression. Compared with conventional treatment options, olutasidenib offers a more personalized therapeutic strategy for eligible patients. Growing adoption of genomic testing, increasing leukemia incidence, and expanding use of biomarker-based therapies continue to strengthen demand within this application segment.
Clinical Trials : Clinical trials represent a rapidly developing application area for olutasidenib as researchers explore its effectiveness in broader hematologic and oncologic indications. The oral therapy is widely utilized by academic medical centers, cancer research institutes, and pharmaceutical developers conducting studies focused on targeted treatment approaches. Clinical investigations are evaluating potential combination regimens, expanded patient populations, and improved treatment outcomes. The growing emphasis on precision oncology and mutation-specific therapies is accelerating interest in olutasidenib across global research networks. This application supports innovation within the oncology sector and contributes to the generation of clinical evidence that may expand future therapeutic opportunities.
Research & Development : Research and development activities play a crucial role in advancing the commercial and clinical potential of olutasidenib. Pharmaceutical companies, biotechnology firms, and academic institutions are utilizing the therapy in studies aimed at understanding molecular oncology pathways and developing next-generation treatment strategies. The oral targeted therapy serves as an important component of ongoing efforts to improve outcomes for patients with genetically defined cancers. Increasing investment in cancer genomics, personalized medicine platforms, and targeted drug discovery programs is supporting growth in this application area. Continued research initiatives are expected to create opportunities for expanded indications, innovative treatment combinations, and broader market adoption.

Impact of Industry Transitions on the Olutasidenib Market

As a core segment of the Pharmaceutical industry, the Olutasidenib market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Broad Chemotherapy Approaches to Precision Oncology Treatments and Transition from General Cancer Care to Biomarker Driven Therapeutics have redefined priorities across the Pharmaceutical sector, influencing how the Olutasidenib market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Broad Chemotherapy Approaches to Precision Oncology Treatments

The oncology industry is undergoing a significant transition from conventional chemotherapy-based treatment models toward precision oncology strategies guided by molecular profiling. Olutasidenib reflects this evolution by targeting specific genetic mutations rather than relying on broad-spectrum cancer treatment approaches. This shift is increasing the importance of genomic testing, companion diagnostics, and personalized treatment planning across hospitals and cancer centers. For example, diagnostic laboratories are expanding molecular testing services to identify eligible patients for targeted therapies. The transition is reshaping pharmaceutical development priorities and creating stronger demand for mutation-specific cancer treatments within the broader hematology and oncology ecosystem.
02

Transition from General Cancer Care to Biomarker Driven Therapeutics

Cancer treatment is increasingly moving toward biomarker-driven therapeutic frameworks that emphasize individualized patient selection and targeted intervention. Olutasidenib benefits from this transition as healthcare providers adopt treatment pathways based on specific genetic characteristics rather than disease type alone. The growing use of biomarker testing is improving treatment precision and supporting more efficient resource allocation within oncology care. For example, healthcare systems are investing in advanced diagnostic infrastructure to expand access to personalized medicine programs. This shift is encouraging collaboration between pharmaceutical companies, diagnostic providers, and research institutions while accelerating innovation across the targeted oncology and precision healthcare industries.